Kailera Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Kailera Therapeutics

12/08/2026 23:22

Kailera Therapeutics Inc KLRA.OQ reported a quarterly adjusted loss of $1.09​​ per share for the quarter ended June 30.  The mean expectation of four analysts for the quarter was for a loss of 75 cents per share. Wall Street expected results to range from -81 cents to -67 cents per share.
Reported revenue was zero​; analysts expected zero. 
Kailera Therapeutics Inc's reported EPS for the quarter was a loss of $1.09​.
The company reported a quarterly loss of $111.31 million.
Kailera Therapeutics Inc shares had fallen by 14.3% this quarter.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 0.9% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is  "buy."
Wall Street's median 12-month price target for Kailera Therapeutics Inc is $52.50, about 64.6% above its last closing price of $18.59
This summary was machine generated from LSEG data August 12 at 10:22 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.75
-1.09
Missed
Mar. 31 2026 
-0.67
-0.64
Beat